Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2025-03-17 Earnings Release
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Pharmanutra || CS ad integrazione e chiarimento
Earnings Release Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated March 17, 2025, titled 'NOTA DI CHIARIMENTO SUL COMUNICATO STAMPA DEL 14 MARZO 2025 RISPETTO ALL'EVOLUZIONE PREVEDIBILE DELLA GESTIONE' (Clarification Note on the Press Release of March 14, 2025, regarding the predictable evolution of management). This document explicitly states it is an 'integrazione e chiarimento' (integration and clarification) of a previous press release concerning management outlook. The structure, use of 'Informazione Regolamentata' (Regulated Information), and the nature of clarifying previous statements suggest it is a specific type of regulatory disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it deals with clarifying business outlook/management guidance, it fits best as a general Regulatory Filing (RNS) or potentially a Management Report (MDA) if the clarification was substantial. However, given the context of clarifying a previous press release regarding management outlook ('Evoluzione prevedibile della gestione'), and the document being short and focused on a specific clarification rather than a comprehensive management discussion, it functions primarily as a regulatory update. The presence of 'Vedi allegato' (See attachment) and the short length (4094 chars) strongly suggests this is an announcement pointing to further information or clarifying a prior announcement, making RNS the most appropriate general regulatory category, or potentially LTR if the clarification related to a legal/regulatory risk, but here it relates to business outlook uncertainty. Given the options, RNS is the safest fallback for a specific regulatory clarification announcement that isn't a standard report type. FY 2024
2025-03-17 Italian
Pharmanutra: Avviso di disponibilità | Notice of availability
AGM Information Classification · 1% confidence The document is a formal announcement titled 'Pharmanutra: Avviso di disponibilità Notice of availability' and explicitly states that the 'Relazioni Illustrative sui punti all'ordine del giorno dell'Assemblea degli azionisti' (Explanatory Reports on the items on the agenda of the Shareholders' Meeting) are available to the public. This structure—a short notice announcing the availability of detailed meeting documents (like proxy materials or explanatory reports for an AGM)—fits the definition of a Report Publication Announcement (RPA). It is not the full AGM presentation (AGM-R) nor the proxy solicitation material itself (PSI), but the notice that those materials are ready for viewing. The document length (6423 chars) is moderate, but the content is purely an announcement referencing other documents related to the 'Assemblea degli azionisti' (Shareholders' Meeting).
2025-03-17 Italian
Pharmanutra_Board of Directors approved the FY 2024 results
Earnings Release Classification · 1% confidence The document is a detailed announcement from PharmaNutra S.p.A. regarding the approval of its FY 2024 financial results by the Board of Directors. It contains comprehensive financial highlights, including revenue, EBITDA, net results, and balance sheet data, as well as management commentary and analysis of the fiscal year. While it summarizes the results, it provides substantive financial data and analysis rather than just a notification of a report's availability. Given the depth of the financial data provided for the full fiscal year, it aligns best with the definition of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers the full fiscal year (FY 2024) and acts as the primary announcement of these results, it is classified as an Earnings Release. FY 2024
2025-03-14 English
Pharmanutra_Consiglio di Amministrazione approva i risultati 2024
Earnings Release Classification · 1% confidence The document is an official press release from PharmaNutra S.p.A. dated March 14, 2025, announcing the approval of the 2024 financial results by the Board of Directors. It contains key financial highlights (revenues, EBITDA, net income, dividends) and a summary of business performance for the fiscal year 2024. While it discusses the 'Progetto di Bilancio' (Draft Financial Statements), it is a summary announcement intended for the market rather than the full, audited annual report document itself. According to the 'Menu vs Meal' rule, this is an Earnings Release (ER) as it provides the initial highlights of the annual financial performance. FY 2024
2025-03-14 Italian
Pharmanutra_Consiglio di Amministrazione approva i risultati 2024
Earnings Release Classification · 1% confidence The document is an official press release from PharmaNutra S.p.A. dated March 14, 2025, announcing the approval of the 2024 financial results by the Board of Directors. It contains key financial highlights (revenues, EBITDA, net income, dividends) and a summary of business performance for the fiscal year 2024. While it discusses the 'Progetto di Bilancio' (Draft Financial Statements), it is a summary announcement intended for the market rather than the full, audited annual report document itself. According to the 'Menu vs Meal' rule, this is an Earnings Release (ER) as it provides the initial highlights of the annual financial performance. FY 2024
2025-03-14 Italian
Pharmanutra_Consiglio di Amministrazione approva i risultati 2024
Earnings Release Classification · 1% confidence The document is an official press release from PharmaNutra S.p.A. dated March 14, 2025, announcing the approval of the 2024 financial results by the Board of Directors. It contains key financial highlights (revenues, EBITDA, net income, dividends) and a summary of business performance for the fiscal year 2024. While it discusses the 'Progetto di Bilancio' (Draft Financial Statements), it is a summary announcement intended for the market rather than the full, audited annual report document itself. According to the 'Menu vs Meal' rule, this is an Earnings Release (ER) as it provides the initial highlights of the annual financial performance. FY 2024
2025-03-14 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.